Eli Lilly and Company Stock News

ROCKVILLE, Md., Aug. 27, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2024 class in AKF's Corporate Membership Program as a Champion-level member. Boehringer Ingelheim and Lilly will help provide financial support for AKF's work to advance kidney disease awareness, prevention, early detection, treatme...

The more affordable vials are marketed toward patients whose health insurance will not reimburse them for the cost of the drug.

Eli Lilly (LLY) reached a key supply milestone Tuesday, announcing the launch of single-dose vials of Zepbound, one of the company's popular weight-loss drugs.

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit weight-loss drugs. Zepbound will be sold for $399-$549 per month, compared to a previous list price of $1,059.

Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than "all other incretin GLP-1 medicines for obesity.

Its tirzepatide reduces the chance of developing diabetes, according to a new study. The population of people who might develop diabetes in the future is very large.

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock edged higher.

The new option is priced at a 50% or more discount compared to other weight-loss drugs.